Healio received an APEX award for a 2024 report on the cloudy future of HIV vaccine research in the age of long-acting ...

Gilead Sciences (GILD) faces stock pressure as changes to the U.S. Preventive Services Task Force could impact PrEP drug ...

Apretude (cabotegravir) – the first injectable type of HIV PrEP – was approved by the FDA in 2021, and is currently covered by Medicaid in Ohio. However, the drug is administered once every two months ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead ...

The European Medicines Agency (EMA) has recommended approving a twice-yearly injectable medication designed to prevent HIV ...

Gilead Sciences, Inc. (NASDAQ: GILD) is one of the top low volatility healthcare stocks to buy now. In a report released on ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug ...

Medical professionals Timothy Holtz and Teri Mills worked with AIDS patients in the 1990s, when treatments were few. With ...

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug aimed at preventing HIV, which ...

Parents with children insured by Medicaid fear changes to the government program mean vaccines will no longer be covered.

Jeremiah Johnson, executive director of PrEP4All, an organization committed to HIV prevention and care, talks about the ...

Long-acting lenacapavir has been shown to be a promising option for HIV PrEP and is now recommended globally by WHO, with a ...